Page-14
18. Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune
dysfunction: distinctive features and clinical relevance. J Hepatol.
2014;61(6):1385-1396.
19. Lario M, Muñoz L, Ubeda M, et al. Defective thymopoiesis and poor
peripheral homeostatic replenishment of T-helper cells cause T-cell
lymphopenia in cirrhosis. J Hepatol. 2013;59(4):723-730.
20. Goel A, Verma A, Tiwari P, et al. Serological Immune Response
Following ChAdOx1 nCoV-19 Vaccine (Covishield®) in Patients with Liver
Cirrhosis. Vaccines (Basel). 2022;10(11):1837.
21. Mohammed AH, Blebil A, Dujaili J, Rasool-Hassan BA. 2020. The risk
and impact of COVID-19 pandemic on immunosuppressed patients: Cancer,
HIV, and solid organ transplant recipients. AIDS Rev .
22:151–157.
22. Lee ARYB, Wong SY, Chai LYA, et al. Efficacy of covid-19 vaccines in
immunocompromised patients: systematic review and meta-analysis. BMJ.
2022;376:e068632.
23. Costiniuk CT, Singer J, Lee T, et al. COVID-19 vaccine
immunogenicity in people with HIV. AIDS. 2023;37(1):F1-F10.
24. Reeg DB, Hofmann M, Neumann-Haefelin C, Thimme R, Luxenburger H.
SARS-CoV-2-Specific T Cell Responses in Immunocompromised Individuals
with Cancer, HIV or Solid Organ Transplants. Pathogens. 2023;12(2):244.
25. Good practice statement on the use of second booster doses for
COVID-19 vaccines 18 August 2022 Background [Internet]. Available
from: https://www.who.int/groups/strategic-advisory.